Russian drugmaker Geropharm demands Ozempic compulsory license

The Russian drugmaker Geropharm has demanded a compulsory license from Denmark’s Novo Nordisk (NOV: N) to produce a generic of Ozempic (semaglutide), which is a drug used for diabetes and the active ingredient is marketed as Wegovy for weight loss, reports The Pharma Letter’s local correspondent.

So far, Geropharm has already appealed to the Moscow Arbitration Court, regarding with this case. While the company does not disclose the exact name of the disputed drug, according to the Russian RBC business paper, citing on its sources this is Ozempic (semaglutide). Geropharm already has a compulsory license to produce an analogue of this medicine - the Russian government issued the corresponding permit to the manufacturer, as well as to another Russian company Promomed, at the end of last year, after Novo Nordisk stopped supplying Ozempic to the country. The license is valid for one year.

Suit also filed against Sanofi over Toujeo